Among a total of 99 identified cases, 79.79% of lymphomas were localized in the stomach, 20.20% in the intestinal tract, and disseminated disease was detected in 35.4% of cases. The estimated 5-year overall survival (OS) and 5-year progression-free

survival (PFS) rates were 73.1% and 65.1%, respectively. The comparison between stomach and intestinal tract lymphomas demonstrated no significant difference in characteristics, but nodal involvement was significantly lower in gastric MALT lymphoma (26.6%) as compared with intestinal tract MALT lymphoma (60%, P = 0.006). The outcomes of gastric and intestinal MALT lymphomas were similar (OS, P = 0.492; PFS, GS-1101 P = 0.408), and so was the survival between proximal and distal gastric lymphomas (OS, P = 0.077; PFS, P = 0.181). Serum lactate dehydrogenase level above normal was identified as the only adverse prognostic factor for both OS and PFS. The clinical characteristics and outcomes demonstrated no significant differences between gastric and intestinal tract MALT lymphomas. Serum lactate dehydrogenase level was an independent prognostic factor for Lenvatinib cell line the survival of GI MALT lymphoma. “
“We read with great interest the article by Kowalik et al.,1 recently published in Hepatology. The authors found that hepatocellular carcinomas (HCCs) developed in mice that were administered diethylnitrosamine

and then repeatedly treated with the mitogen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene. These mice showed increased expression levels of the transcriptional coactivator

Erastin ic50 Yes-associated protein (YAP), and these increased expression levels were associated with the down-regulation of miR-375 expression, which is known to control YAP expression,2 and with enhanced levels of alpha-fetoprotein (AFP), which is encoded by the target gene of YAP. However, the inverse association between miR-375 and AFP expression was not dose-dependent. We describe our single-center experience with 157 HCC patients who underwent primary resection. The patients were divided into two groups on the basis of the mean levels of miR-375 expression in all tumor tissues, which were determined using an miRNA array and validated by real-time polymerase chain reaction (PCR) analysis. Ten samples from living donor livers (mean [SD] miRNA expression, 13.85 [0.57]) were used as controls. miR-375 expression was down-regulated in HCCs. The clinicopathologic characteristics of the patients are summarized in Table 1. We found that preoperative serum AFP levels in the group showing less reduction in miR-375 expression were significantly higher than those in the group showing higher levels of reduction in miR-375 expression. The findings for the other factors were comparable in both groups. In summary, our results suggest that AFP expression in HCCs was not solely regulated by the axis of miR-375-YAP-AFP. Cheng-Maw Ho M.D.